Vaporox has developed a patented and ultrasonic technology called Vaporous Hyperoxia Therapy


Vaporox has 510(k) clearance from the FDA for VHT. (Credit: Gerd Altmann from Pixabay)

Bioventus, a provider of active healing solutions, has made a minority investment in diabetic foot ulcer (DFU) wound healing therapy developer Vaporox.

Based in Denver of Colorado, Vaporox has developed a patented and ultrasonic technology called Vaporous Hyperoxia Therapy (VHT).

Vaporox has already secured 510(k) clearance from the US Food and Drug Administration (FDA) for VHT, which offers low frequency, non-contact and non-thermal ultrasound to treat wound.

VHT is said to have the ability to heal around 85% of DFUs, which have been insensitive to the current standard of care

Bioventus business development and strategy senior vice president Chris Yamamoto said: “The investment in Vaporox represents an attractive valuation entry point and allows us to take a phased approach to a potential acquisition.

“We see a significant opportunity ahead of Bioventus to consolidate highly strategic assets that we expect will ultimately drive accretive revenue growth to our business.”

In July last year, Bioventus invested $15m in Israeli medical device company CartiHeal. The deal provided an option to Bioventus to acquire CartiHeal if its cartilage treatment implant Agili-C secures FDA approval.

Bioventus has developed StimRouter peripheral nerve stimulation device and EXOGEN ultrasound bone healing system. It offers a range of products to foot and ankle surgeons.

Based in Durham of North Carolina, Bioventus employs more than 700 people across the world.

In March, the company announced the acquisition of  Bioness, a provider of neuromodulation and rehabilitation medical devices through its innovative peripheral nerve stimulation (PNS) therapy and premium rehabilitation solutions.

The acquisition comprised the entire portfolio of Bioness products and its research and development pipeline.